A number of recent clinical trials testing the combination of 5-fluorouracil (5-FU) and gemcitabine in patients with advanced pancreatic adenocarcinoma have shown a significant clinical response rate, but also significant toxicity. As the two antimetabolites may interact at several biochemical levels along their pathways of activation, we investigated whether gemcitabine (GEM) affects 5-FU pharmacokinetics in cancer patients. Thus, we compared 5-FU pharmacokinetics in two groups of patients with various cancers who received the same schedule of 5-FU and folinic acid (FUFA), with or without GEM. There was a significant increase in systemic (5-FU) exposure and toxicity in the FUFA plus GEM group. Our finding may be useful in designing future studies of the combination in order to reduce the occurrence of side-effects and to maximise the antitumour activity.
Scheda prodotto non validato
Scheda prodotto in fase di analisi da parte dello staff di validazione
|Titolo:||Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients.|
|Citazione:||Correale, P., Cerretani, D., Marsili, S., Pozzessere, D., Petrioli, R., Messinese, S., et al. (2003). Gemcitabine increases systemic 5-fluorouracil exposure in advanced cancer patients. EUROPEAN JOURNAL OF CANCER, 39(11), 1547-1551.|
|Appare nelle tipologie:||1.1 Articolo in rivista|